Literature DB >> 24570075

Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues.

Dong Gui Hu1, Theresa E Hickey, Connie Irvine, Dhilushi Dodampege Wijayakumara, Lu Lu, Wayne D Tilley, Luke A Selth, Peter I Mackenzie.   

Abstract

The androgen receptor (AR) is widely expressed in human tissues and has biological function in many male and female organs. In particular, the AR plays a critical role in the biology and pathology of the prostate gland. AR activity inhibits breast growth and has pleiotropic actions in breast cancer that are subtype-dependent. Expression of AR splice variants (ARVs) and their role in prostate carcinogenesis has been elucidated in recent studies. We hypothesised that ARVs are also expressed in breast cancers and other hormone sensitive tissues. Herein, the expression of five previously identified ARV transcripts with documented transcriptional capacity (AR-V1, -V3, -V4, -V7, and -V9) was examined in 6 breast (MFM223, MDA-MB-453, MDA-MB-231, ZR75.1, MCF-7, T47D), two prostate (VCaP, LNCaP), and one liver (HepG2) cancer cell lines, a human embryonic kidney cell line (HEK293), and a panel of RNAs representing 21 different human tissues. Four ARVs (V1, V3, V7, V9) were detected to some degree in almost all cell lines and tissues. In addition, four novel ARVs containing a cryptic exon 9 (CE9) were detected in MDA-MB-453 and VCaP cells. Sequencing of ARV amplicons revealed a single nucleotide substitution within CE3 in lung and placental tissue samples that could be translated as an Ile (ATT)>Val (GTT) substitution in the AR-V7 variant protein. Collectively, these data provides insight into the potential complexity of AR transcriptional splicing events in breast cancer cell lines and diverse human tissues, thereby establishing a rationale for further exploration of ARVs in breast cancer and other human pathologies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24570075     DOI: 10.1007/s12672-014-0171-4

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  41 in total

Review 1.  Progress of molecular targeted therapies for prostate cancers.

Authors:  Weihua Fu; Elena Madan; Marla Yee; Hongtao Zhang
Journal:  Biochim Biophys Acta       Date:  2011-11-29

2.  AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.

Authors:  Gang Liu; Cynthia Sprenger; Shihua Sun; Kathryn Soriano Epilepsia; Kathleen Haugk; Xiaotun Zhang; Ilsa Coleman; Peter S Nelson; Stephen Plymate
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

3.  Characterization and expression of a cDNA encoding the human androgen receptor.

Authors:  W D Tilley; M Marcelli; J D Wilson; M J McPhaul
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

4.  Identification of androgen receptor variants in testis from humans and other vertebrates.

Authors:  S S Laurentino; P I S Pinto; J Tomás; J E Cavaco; M Sousa; A Barros; D M Power; A V M Canário; S Socorro
Journal:  Andrologia       Date:  2012-06-26       Impact factor: 2.775

5.  A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities.

Authors:  Rong Hu; William B Isaacs; Jun Luo
Journal:  Prostate       Date:  2011-03-28       Impact factor: 4.104

6.  Identification of molecular apocrine breast tumours by microarray analysis.

Authors:  Pierre Farmer; Herve Bonnefoi; Veronique Becette; Michele Tubiana-Hulin; Pierre Fumoleau; Denis Larsimont; Gaetan Macgrogan; Jonas Bergh; David Cameron; Darlene Goldstein; Stephan Duss; Anne-Laure Nicoulaz; Cathrin Brisken; Maryse Fiche; Mauro Delorenzi; Richard Iggo
Journal:  Oncogene       Date:  2005-07-07       Impact factor: 9.867

7.  Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.

Authors:  Yingming Li; Majid Alsagabi; Danhua Fan; G Steven Bova; Ahmed H Tewfik; Scott M Dehm
Journal:  Cancer Res       Date:  2011-01-19       Impact factor: 12.701

Review 8.  The androgen receptor in health and disease.

Authors:  Takahiro Matsumoto; Matomo Sakari; Maiko Okada; Atsushi Yokoyama; Sayuri Takahashi; Alexander Kouzmenko; Shigeaki Kato
Journal:  Annu Rev Physiol       Date:  2012-11-13       Impact factor: 19.318

9.  Estrogen receptor alpha, fos-related antigen-2, and c-Jun coordinately regulate human UDP glucuronosyltransferase 2B15 and 2B17 expression in response to 17beta-estradiol in MCF-7 cells.

Authors:  Dong Gui Hu; Peter I Mackenzie
Journal:  Mol Pharmacol       Date:  2009-06-01       Impact factor: 4.436

Review 10.  Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.

Authors:  Howard I Scher; Grant Buchanan; William Gerald; Lisa M Butler; Wayne D Tilley
Journal:  Endocr Relat Cancer       Date:  2004-09       Impact factor: 5.678

View more
  30 in total

1.  Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.

Authors:  Sumit Isharwal; Shrey Modi; Nivedita Arora; Charles Uhlrich; Bhuwan Giri; Usman Barlass; Ayman Soubra; Rohit Chugh; Scott M Dehm; Vikas Dudeja; Ashok Saluja; Sulagna Banerjee; Badrinath Konety
Journal:  Prostate       Date:  2017-02-01       Impact factor: 4.104

Review 2.  Are androgen receptor variants a substitute for the full-length receptor?

Authors:  Ji Lu; Travis Van der Steen; Donald J Tindall
Journal:  Nat Rev Urol       Date:  2015-02-10       Impact factor: 14.432

3.  Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms.

Authors:  J Feng; L Li; N Zhang; J Liu; L Zhang; H Gao; G Wang; Y Li; Y Zhang; X Li; D Liu; J Lu; B Huang
Journal:  Oncogene       Date:  2016-11-28       Impact factor: 9.867

4.  The Y-located proto-oncogene TSPY exacerbates and its X-homologue TSPX inhibits transactivation functions of androgen receptor and its constitutively active variants.

Authors:  Yunmin Li; Dong Ji Zhang; Yun Qiu; Tatsuo Kido; Yun-Fai Chris Lau
Journal:  Hum Mol Genet       Date:  2017-03-01       Impact factor: 6.150

5.  Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.

Authors:  Valerie N Barton; Nicholas C D'Amato; Michael A Gordon; Hanne T Lind; Nicole S Spoelstra; Beatrice L Babbs; Richard E Heinz; Anthony Elias; Paul Jedlicka; Britta M Jacobsen; Jennifer K Richer
Journal:  Mol Cancer Ther       Date:  2015-02-23       Impact factor: 6.261

Review 6.  Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.

Authors:  Valerie N Barton; Nicholas C D'Amato; Michael A Gordon; Jessica L Christenson; Anthony Elias; Jennifer K Richer
Journal:  Horm Cancer       Date:  2015-07-23       Impact factor: 3.869

7.  An imaging agent to detect androgen receptor and its active splice variants in prostate cancer.

Authors:  Yusuke Imamura; Amy H Tien; Jinhe Pan; Jacky K Leung; Carmen A Banuelos; Kunzhong Jian; Jun Wang; Nasrin R Mawji; Javier Garcia Fernandez; Kuo-Shyan Lin; Raymond J Andersen; Marianne D Sadar
Journal:  JCI Insight       Date:  2016-07-21

8.  NF-κB and androgen receptor variant expression correlate with human BPH progression.

Authors:  David C Austin; Douglas W Strand; Harold L Love; Omar E Franco; Alex Jang; Magdalena M Grabowska; Nicole L Miller; Omar Hameed; Peter E Clark; Jay H Fowke; Robert J Matusik; Ren J Jin; Simon W Hayward
Journal:  Prostate       Date:  2015-12-28       Impact factor: 4.104

Review 9.  Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer.

Authors:  Jessica L Christenson; Jane B Trepel; Haythem Y Ali; Sunmin Lee; Joel R Eisner; Edwina S Baskin-Bey; Anthony D Elias; Jennifer K Richer
Journal:  Horm Cancer       Date:  2018-01-16       Impact factor: 3.869

10.  Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis.

Authors:  Kimberley Katleba; Alan P Lombard; Maria-Malvina Tsamouri; Han Bit Baek; Kristine S Nishida; Stephen J Libertini; Alexander J Platero; Ai-Hong Ma; Chong-Xian Pan; Paramita M Ghosh; Maria Mudryj
Journal:  Cancer Lett       Date:  2021-02-04       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.